{"id":"tislelizumab-cisplatin-gemcitabine-and-trilaciclib","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL2447941","moleculeType":"Small molecule","molecularWeight":"629.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tislelizumab works by binding to the PD-1 receptor on T cells, preventing the interaction with PD-L1 on tumor cells. This prevents the tumor cells from evading the immune response, allowing the T cells to attack and kill the cancer cells. The combination with cisplatin and gemcitabine, and trilaciclib, a CDK4/6 inhibitor, aims to enhance the anti-tumor effect.","oneSentence":"Tislelizumab is a PD-1 inhibitor that blocks the PD-1 receptor on T cells, preventing the interaction with PD-L1 on tumor cells and thereby enhancing the immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:59.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Small cell lung cancer"},{"name":"Esophageal squamous cell carcinoma"},{"name":"Gastric or gastroesophageal junction adenocarcinoma"},{"name":"Hepatocellular carcinoma"},{"name":"Urothelial carcinoma"},{"name":"Cervical cancer"},{"name":"Malignant pleural mesothelioma"}]},"trialDetails":[{"nctId":"NCT06364904","phase":"PHASE3","title":"A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10","conditions":"Bladder Cancer","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib","genericName":"Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a PD-1 inhibitor that blocks the PD-1 receptor on T cells, preventing the interaction with PD-L1 on tumor cells and thereby enhancing the immune response against cancer cells. Used for Non-small cell lung cancer, Small cell lung cancer, Esophageal squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}